Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
Piper-Vallillo AJ, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml JM, Neal JW, Piotrowska Z. Piper-Vallillo AJ, et al. Among authors: shaverdashvili k. JTO Clin Res Rep. 2022 Apr 21;3(6):100328. doi: 10.1016/j.jtocrr.2022.100328. eCollection 2022 Jun. JTO Clin Res Rep. 2022. PMID: 35637759 Free PMC article.
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
Tompkins W, Grady CB, Hwang WT, Chandrasekhara K, McCoach C, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Montenegro GLB, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Marmarelis ME, Sun L. Tompkins W, et al. Among authors: shaverdashvili k. JTO Clin Res Rep. 2024 Mar 26;5(8):100669. doi: 10.1016/j.jtocrr.2024.100669. eCollection 2024 Aug. JTO Clin Res Rep. 2024. PMID: 39157674 Free PMC article.
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Stalker M, Grady CB, Watts A, Hwang WT, Chandrasekhara K, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Bravo Montenegro GL, Tompkins W, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Sun L, Marmarelis ME. Stalker M, et al. Among authors: shaverdashvili k. JTO Clin Res Rep. 2024 Nov 12;6(1):100765. doi: 10.1016/j.jtocrr.2024.100765. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758601 Free PMC article.
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.
Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. Shaverdashvili K, et al. EClinicalMedicine. 2023 Nov 21;66:102317. doi: 10.1016/j.eclinm.2023.102317. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192592 Free PMC article.
13 results